CubeSmart (CUBE) earnings date, results and what the price requires
NYSE · SEC CIK 0001298675 · SEC filings checked Oct 17, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 31, 2026 | Announced; figures arrive with the 10-Q | — | — | Filing |
| Mar 31, 2026 | May 1, 2026 | $281.9M | — | $0.36 | Filing |
| Dec 31, 2025 | Feb 27, 2026 | $282.7M | — | $0.35 | Filing |
| Sep 30, 2025 | Oct 31, 2025 | $285.1M | — | $0.36 | Filing |
| Jun 30, 2025 | Aug 1, 2025 | $282.3M | — | $0.36 | Filing |
| Mar 31, 2025 | May 2, 2025 | $273.0M | — | $0.39 | Filing |
| Dec 31, 2024 | Feb 28, 2025 | $267.7M | — | $0.45 | Filing |
| Sep 30, 2024 | Nov 1, 2024 | $270.9M | — | $0.44 | Filing |
| Jun 30, 2024 | Aug 2, 2024 | $266.2M | — | $0.41 | Filing |
What would CubeSmart have to report for its valuation to change?
At $38.99, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 18.4% a year, to $3.33. On that path the next quarter needs diluted EPS near $0.43, against $0.36 in the quarter ended Jun 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | 18.4% | 18.4% |
| EPS needed in final year | $3.33 | $3.33 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. CUBE goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.